Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantra - FiercePharma
- Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantra FiercePharma
- Pfizer's earnings outlook disappoints after Viagra loses patent protection and Lyrica faces same fate CNBC
- Pfizer quarterly profit in line, touts pipeline of future products Yahoo Finance
- Pfizer Tops Q4 Earnings But Guides for Weaker 2019 as Lyrica Exclusivity Ends TheStreet.com
- Pfizer's Outlook Disappoints as Drugmaker Focuses on Pipeline Bloomberg
- View full coverage on Google News
Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantra - FiercePharma
![Pfizer's suffering from generics, but 'innovation for growth'—not big M&A—is still the mantra - FiercePharma]()
Reviewed by Geeky Gadgets
on
02:09
Rating:
No comments: